Last Updated on October 14, 2024 by The Health Master
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market mesalamine extended-release capsules in the strength of 0.375 g.
Mesalamine extended-release capsules are indicated for the maintenance of remission of ulcerative colitis in adults.
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 320 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Cipla gets USFDA nod for generic Difluprednate Ophthalmic Emulsion
Alembic gets USFDA nod for Clomipramine HCL Capsules
Zydus Cadila gets final nod from USFDA for Fulvestrant injection
USFDA inspection ends with ‘Zero’ observations: Alkem
Granules Pharma clears USFDA audit
Zydus Cadila gets USFDA nod for Ibrutinib tablets
42 FDA Officers honoured on 15th August 2021: Independence Day
Govt removes DPCO 2013’s this clause on ceiling price revision
Latest Notifications regarding Pharmaceuticals
Ceiling Prices of drugs: Govt takes measures to mandatorily revise …
First Nasal Vaccine gets nod for Phase 2 trial: Bharat Biotech
Green Ministry drops Antibiotic effluent limits from new rules
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
